PE20040832A1 - DERIVATIVES OF INDOLIL PIRAZINONE - Google Patents

DERIVATIVES OF INDOLIL PIRAZINONE

Info

Publication number
PE20040832A1
PE20040832A1 PE2003001136A PE2003001136A PE20040832A1 PE 20040832 A1 PE20040832 A1 PE 20040832A1 PE 2003001136 A PE2003001136 A PE 2003001136A PE 2003001136 A PE2003001136 A PE 2003001136A PE 20040832 A1 PE20040832 A1 PE 20040832A1
Authority
PE
Peru
Prior art keywords
atoms
quinoxalinone
indol
halo
alkyl
Prior art date
Application number
PE2003001136A
Other languages
Spanish (es)
Inventor
Gaetan H Ladouceur
Jacques Dumas
Cheng Bi
Brian Bear
Michael R Turner
Robert Sibley
Michael J Burke
James Cook
David R Britteli
Gang Chen
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20040832A1 publication Critical patent/PE20040832A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE INDOLIL DE FORMULA I, SUS SALES O ESTERES FARMACEUTICAMENTE ACEPTABLES, EN DONDE Ar ES UN ANILLO AROMATICO DE 6 MIEMBROS CON 0, 1 o 2 ATOMOS DE N; R1 Y R2 SON, INDEPENDIENTEMENTE ENTRE SI, H, HALO, CF3, ENTRE OTROS; CON LA CONDICION DE QUE CUANDO Ar CONTIENE 1 o 2 ATOMOS DE N, R1 Y R2 DEBEN SER, CADA UNO, H; Y R1 Y R2 JUNTO CON LOS ATOMOS DE C ADYACENTES A LOS CUALES ESTAN UNIDOS FORMAN UN ANILLO SELECCIONADO DE BENZO, DIOXOLO E IMIDAZO, DONDE DICHO IMIDAZO ESTA OPCIONALMENTE SUSTITUIDO HASTA 2 VECES CON ALQUILO C1-C3; CON LA CONDICION DE QUE R1 Y R2 JUNTO CON LOS ATOMOS DE C ADYACENTES A LOS QUE ESTAN UNIDOS FORMAN UN ANILLO SOLO CUANDO Ar NO CONTIENE ATOMOS DE N; R3 ES H, ALQUILO C1-C4, H, NO2, NH2, ENTRE OTROS; R4 ES H, OH, HALO, CN, ENTRE OTROS; R5 ES H, HALO, CN, ALCOXI C1-C6 o ALQUILO C1-C6; R11 Y R12 SON, INDEPENDIENTEMENTE ENTRE SI, H, F, O Cl; CON LA CONDICION DE QUE CUANDO UNO DE R11 Y R12 ES F o Cl, EL OTRO DEBE SER H. SON COMPUESTOS PREFERIDOS: 3-(1H-INDOL-2-IL)-2(1H)-QUINOXALINONA; 3-(3-NITRO-1H-INDOL-2-IL)-2(1H)-QUINOXALINONA; 3-(3-AMINO-1H-INDOL-2-IL)-2(1H)-QUINOXALINONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN METODO. ESTOS COMPUESTOS SON UTILES PARA TRATAR TRASTORNOS HIPERPROLIFERATIVOSREFERS TO COMPOUNDS DERIVED FROM INDOLIL OF FORMULA I, ITS PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS, WHERE Ar IS A 6-MEMBER AROMATIC RING WITH 0, 1, or 2 N ATOMS; R1 AND R2 ARE, INDEPENDENTLY BETWEEN IF, H, HALO, CF3, BETWEEN OTHERS; WITH THE CONDITION THAT WHEN Ar CONTAINS 1 or 2 ATOMS OF N, R1 AND R2 MUST EACH H; AND R1 AND R2 TOGETHER WITH THE ADJACENT C ATOMS TO WHICH THEY ARE UNITED FORM A SELECTED RING OF BENZO, DIOXOLO AND IMIDAZO, WHERE SAID IMIDAZO IS OPTIONALLY SUBSTITUTED UP TO 2 TIMES WITH C1-C3 ALKYL; WITH THE CONDITION THAT R1 AND R2 TOGETHER WITH THE ADJACENT C ATOMS TO WHICH THEY ARE UNITED, MAKE A RING ONLY WHEN Ar DOES NOT CONTAIN N ATOMS; R3 IS H, C1-C4 ALKYL, H, NO2, NH2, AMONG OTHERS; R4 IS H, OH, HALO, CN, AMONG OTHERS; R5 IS H, HALO, CN, C1-C6 ALCOXY or C1-C6 ALKYL; R11 AND R12 ARE, INDEPENDENTLY BETWEEN IF, H, F, OR Cl; WITH THE CONDITION THAT WHEN ONE OF R11 AND R12 IS F or Cl, THE OTHER MUST BE H. THE PREFERRED COMPOUNDS ARE: 3- (1H-INDOL-2-IL) -2 (1H) -QUINOXALINONE; 3- (3-NITRO-1H-INDOL-2-IL) -2 (1H) -QUINOXALINONE; 3- (3-AMINO-1H-INDOL-2-IL) -2 (1H) -QUINOXALINONE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A METHOD. THESE COMPOUNDS ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS

PE2003001136A 2002-11-12 2003-11-11 DERIVATIVES OF INDOLIL PIRAZINONE PE20040832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42549002P 2002-11-12 2002-11-12
US46091503P 2003-04-07 2003-04-07
US48420203P 2003-06-30 2003-06-30

Publications (1)

Publication Number Publication Date
PE20040832A1 true PE20040832A1 (en) 2005-01-27

Family

ID=32314888

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001136A PE20040832A1 (en) 2002-11-12 2003-11-11 DERIVATIVES OF INDOLIL PIRAZINONE

Country Status (17)

Country Link
EP (1) EP1565455A1 (en)
JP (1) JP2006509840A (en)
KR (1) KR20050072824A (en)
AR (1) AR043059A1 (en)
AU (1) AU2003290744A1 (en)
BR (1) BR0316169A (en)
CA (1) CA2505819A1 (en)
EC (1) ECSP055851A (en)
HR (1) HRP20050496A2 (en)
MA (1) MA27557A1 (en)
MX (1) MXPA05004779A (en)
NO (1) NO20052796D0 (en)
PE (1) PE20040832A1 (en)
PL (1) PL376867A1 (en)
TW (1) TW200418834A (en)
UY (1) UY28074A1 (en)
WO (1) WO2004043950A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005054201A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP2007512331A (en) * 2003-11-21 2007-05-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン Indolyl-thieno'3,4-B useful for the treatment of hyperproliferative diseases and diseases associated with angiogenesis! Pyrazin-3-one derivatives
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
DE602005026391D1 (en) 2004-06-30 2011-03-31 Janssen Pharmaceutica Nv CHINAZOLINONE DERIVATIVES AS PARP HEMMER
EP1771175B1 (en) 2004-06-30 2015-12-23 Janssen Pharmaceutica NV Phthalazine derivatives as parp inhibitors
AU2005259190B2 (en) 2004-06-30 2011-05-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as PARP inhibitors
BRPI0517734A (en) 2004-11-17 2008-10-21 Korea Res Inst Chem Tech 1 - [(6,7-substituted alkoxyquinoxalinyl) aminocarbonyl] -4- (hetero) arylpiperazine derivatives
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
ES2493466T3 (en) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Apoptosis promoters
WO2008016123A1 (en) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
MX2010010406A (en) 2008-03-27 2010-10-25 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors.
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
EP2352725A1 (en) * 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
RU2715893C2 (en) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Combination of inhibitor fgfr and inhibitor igf1r
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
HUE053654T2 (en) 2014-03-26 2021-07-28 Astex Therapeutics Ltd Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
JP6510556B2 (en) * 2014-04-18 2019-05-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Quinoxaline compounds and uses thereof
EP3247705B1 (en) 2015-01-20 2019-11-20 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
SI3353177T1 (en) 2015-09-23 2020-08-31 Janssen Pharmaceutica Nv Tricyclic heterocycles for the treatment of cancer
WO2023050007A1 (en) * 2021-09-29 2023-04-06 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
WO2024069592A1 (en) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Also Published As

Publication number Publication date
KR20050072824A (en) 2005-07-12
AR043059A1 (en) 2005-07-13
NO20052796L (en) 2005-06-09
CA2505819A1 (en) 2004-05-27
UY28074A1 (en) 2004-05-31
NO20052796D0 (en) 2005-06-09
MXPA05004779A (en) 2005-07-22
JP2006509840A (en) 2006-03-23
EP1565455A1 (en) 2005-08-24
AU2003290744A1 (en) 2004-06-03
HRP20050496A2 (en) 2006-06-30
MA27557A1 (en) 2005-10-03
BR0316169A (en) 2005-09-27
PL376867A1 (en) 2006-01-09
TW200418834A (en) 2004-10-01
WO2004043950A1 (en) 2004-05-27
ECSP055851A (en) 2005-09-20

Similar Documents

Publication Publication Date Title
PE20040832A1 (en) DERIVATIVES OF INDOLIL PIRAZINONE
AR038136A1 (en) CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
PE20060842A1 (en) AMINO-IMIDAZOLONES FOR THE INHIBITION OF B-SECRETASE
AR043111A1 (en) MONOACILATED DERIVATIVES OF O-PHENYLENDIAMINS
UY28135A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8547901A1 (en) 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY
GB0507601D0 (en) Compounds
PE20091376A1 (en) DERIVATIVES OF PHENYLAMINE AS BETA-AMYLOID MODULATORS
PE20061297A1 (en) CHROME AND CHROME DERIVED COMPOUNDS MODULATING THE SEROTONIN 5-HT2C RECEPTOR
UY26727A1 (en) USEFUL TROPANIC DERIVATIVES IN THERAPY
PE20030922A1 (en) PYRIDINE AND QUINOLINE DERIVATIVES
PE20030808A1 (en) HETEROCYCLIC TRICYCLE DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS
AR037489A1 (en) REPLACED KINOLINS AND PROCESS FOR PREPARATION
EA200970461A1 (en) SUBSTITUTED DERIVATIVES 3-ISOBUTYL-9,10-DIMETOXI-1,3,4,6,7,11b-HEXAHYDRO-2H-PYRIDO [2,1-a] IZOHINOLIN-2-OLA AND RELATED METHODS
HK1131136A1 (en) Substituted spirochromanone derivatives as acc inhibitors
AR055171A1 (en) CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC RECEIVER
UY29427A1 (en) SUBSTITUTED DERIVATIVES OF 2,3,4,5- TETRAHIDRO-1H-PIRIDO (4,3-B) INDOL, COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
AR060729A1 (en) AGONIST COMPOUNDS OF MUSCARINIC RECEPTORS
AR053092A1 (en) COMPOUNDS DERIVED FROM PHENOXYACETIC ACID AND INTERMEDIATE SYNTHESIS COMPOUNDS
PE20100737A1 (en) NEW COMPOUNDS
PE20081192A1 (en) PAIN TREATMENT
ES2188957T3 (en) N- (4- (HETEROARILMETIL) FENIL) -HETEROARILAMINAS.
DE602006019221D1 (en) OF DOPAMINE D3 RECEPTORS
MA30756B1 (en) CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS ANTAGONISTS BY-1
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof

Legal Events

Date Code Title Description
FC Refusal